159 related articles for article (PubMed ID: 38067371)
1. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom.
Assaf C; Illidge TM; Waser N; He M; Li T; Zomas A; Bent-Ennakhil N; Little M; Ortiz-Romero PL; Pimpinelli N; Dalal M; Bagot M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067371
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
3. Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries.
Assaf C; Waser N; Bagot M; He M; Li T; Dalal M; Gavini F; Trinchese F; Zomas A; Little M; Pimpinelli N; Ortiz-Romero PL; Illidge TM
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008309
[TBL] [Abstract][Full Text] [Related]
4. Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study.
Querfeld C; Nelson WW; Gor D; Pashos CL; Doan QV; Turini M; Angello JT; Geskin LJ
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2781-2795. PubMed ID: 36284059
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience.
Polgárová K; Polívka J; Kodet O; Klener P; Trněný M
Front Oncol; 2022; 12():884091. PubMed ID: 35747818
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China: A 12-Year Review.
Chen Z; Lin Y; Qin Y; Qu H; Zhang Q; Li Y; Wen Y; Sun J; Tu P; Gao P; Wang Y
JAMA Dermatol; 2023 Oct; 159(10):1059-1067. PubMed ID: 37585188
[TBL] [Abstract][Full Text] [Related]
8. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides).
Quirós PA; Jones GW; Kacinski BM; Braverman IM; Heald PW; Edelson RL; Wilson LD
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):1027-35. PubMed ID: 9276369
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis.
Tsang Y; Gu T; Sharma G; Raspa S; Drake B; Tan H
J Dermatolog Treat; 2018 Dec; 29(8):747-753. PubMed ID: 29733229
[TBL] [Abstract][Full Text] [Related]
10. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
[TBL] [Abstract][Full Text] [Related]
11. Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome.
Patrawala SA; Broussard KC; Wang L; Zic JA
Dermatol Online J; 2016 May; 22(5):. PubMed ID: 27617516
[TBL] [Abstract][Full Text] [Related]
12. Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description.
D'Agostino P; Kent A; Sharp E; Schmidt F; Turini M
Drugs Context; 2020; 9():. PubMed ID: 32821261
[TBL] [Abstract][Full Text] [Related]
13. Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.
Wu PA; Huang V; Bigby ME
Br J Dermatol; 2014 May; 170(5):1015-20. PubMed ID: 24841586
[TBL] [Abstract][Full Text] [Related]
14. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
15. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
16. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
O'Donnell M; Zaya R; Correia E; Krishnasamy S; Sahu J; Shi W; Cha J; Alpdogan SO; Porcu P; Nikbakht N
J Am Acad Dermatol; 2022 Jun; 86(6):1285-1292. PubMed ID: 34273458
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
19. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides.
Wilson LD; Jones GW; Kim D; Rosenthal D; Christensen IR; Edelson RL; Heald PW; Kacinski BM
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):54-60. PubMed ID: 10863224
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
